Helison Pereira do CarmoI; Karla ReichertI; Daniela Diógenes de CarvalhoI; Lindemberg da Mota Silveira-FilhoI; Karlos VilarinhoI; Pedro OliveiraI; Orlando PetrucciI
ABSTRACTObjective: The present study aimed the functional recovery evaluation after long term of cardiac arrest induced by Custodiol (crystalloid-based) versus del Nido (blood-based) solutions, both added lidocaine and pinacidil as cardioplegic agents. Experiments were performed in isolated rat heart perfusion models.
ATP = Adenosine triphosphate
CEUA = Ethics Committee on the Use of Animals
COBEA = Brazilian Council for Animal Experimentation
CR = Coronary resistance
IR = Ischemia and reperfusion
LV = Left ventricle
RP = Rate pressure product
SEM = Standard error of mean
Unicamp = Universidade Estadual de Campinas
Cardioplegic solution administration in open-heart surgeries has been the main strategy enable to antagonize the effects of global ischemia and reperfusion (IR). Cardioplegic arrest in combination with hypothermia corresponds to a standard method to reduce cardiac metabolism during the period of absence of oxygen and substrate, avoiding the collapse of contractile function after reperfusion[1,2].
Despite being essential, this scientific field faces a major challenge in determining a single type of cardioplegic solution protocol amidst a variety of surgical procedures. A pharmacological approach to drugs that act as cardioplegic agents makes this puzzle even more difficult to understand. In the presence of cardioplegic agents, these solutions can block or open ion channels present in the sarcolemma, influencing on the ion dynamic between extra and intracellular means.
In the present study, two cardioplegic agents with distinct actions on ion channels were evaluated, followed by (I) pinacidil, a potassium channel opener, and (II) lidocaine, a sodium channel blocker. Rationally, two different types of solution, very eminent in clinical practice, were elected to drive these drugs on myocardium during global ischemia.
Firstly, Custodiol solution (Custodiol®-HTK), commonly known as HTK solution (histidine/tryptophan/alpha-ketoglutarate) and which has been used primarily in organ preservation, was conceived as an alternative to crystalloid hyperkalemic cardioplegic solutions[4,5]. Custodiol solution has been used in some countries as the first choice for conventional cardiac surgeries, mainly in myocardial preservation. It is considered a type of microplegia or cardioplegia solution with intracellular action due to reduction of potassium, sodium, and calcium concentration, resulting in cardiac arrest by polarization and avoiding damages from hypercontractures related to the depolarized arrest. In addition, Custodiol solution has an important buffering effect attributed to the amino acid histidine, which is important in controlling the balance of hydrogen ion levels released during a long period of ischemia[7,8].
Secondly, del Nido cardioplegia, initially developed to be used in a single dose in neonatal surgeries, is classified as a modified hyperkalemic type due to high potassium concentration, although the lidocaine in its composition avoids the ionic imbalance by blocking sodium current flow[9-11]. This sodium channel blockage prevents intracellular calcium overload, avoiding contractile dysfunction after reperfusion. Lidocaine is a selective and reversible blocker frequently used in clinical practice for the treatment of ventricular tachycardia and also has been assisted recovery hearts submitted to IR in experimental models[12,13].
This study aimed to evaluate cardioplegic solutions under pharmacological modification. Pinacidil was added to both solutions and lidocaine only to the Custodiol solution, since del Nido cardioplegia original formulation already has this agent. Cardioplegic solutions were termed as Custodiol-LP and del Nido-LP. The main goal was to evaluate functional recovery after 3 hours of ischemia and 90 minutes of reperfusion. Moreover, cardiomyocyte integrity by alpha-fodrin degradation was also evaluated from heart samples collected at the end of the protocol.
A total of 18 male Wistar rats weighing 250-350 g were used in this study, which was approved by the Ethics Committee on the Use of Animals (CEUA) of the Universidade Estadual de Campinas (Unicamp) and follows the ethic statements of the "Guide to the Care and Use of Laboratory Animals", published by the National Institute of Health of USA (NIH Publication No. 85-23, revised 1996), and the Brazilian Council for Animal Experimentation (COBEA).
Surgical Protocol for Heart Perfusion
All animals received sodium thiopental anaesthesia (80 mg/kg) and sodium heparin (2,500 IU/kg) intraperitoneally. Then, a bilateral thoracotomy was performed exposing the heart to cardiectomy. The aorta was fixed to the system cannula with silk suture 4-0 and the perfusion was kept under constant pressure throughout the experiment. The catheter with latex balloon connected to the transducer pressure probe was inserted through the mitral valve and allocated to the left ventricle (LV). LV functional measurements of developed pressure, maximum dP/dt, minimum dP/dt, and rate pressure product (RPP) and the coronary resistance (CR) were done.
Experimental Groups and Protocol
The hearts were assigned to one of the following three groups: control (n=4), Custodiol-LP (n=6) and del Nido-LP (n=6). They were initially perfused for 10 minutes stabilization to obtain baseline measurements. Cardiac arrest was induced with a single dose of cardioplegia (30 ml/kg), and the hearts were maintained in global ischemia at 4°C for 3 hours. Reperfusion was performed by re-establishing the heart perfusion.
Cardioplegic Solutions Preparation
The Custodiol solution was acquired from a commercial vendor (Table 1). Blood cardioplegia del Nido was prepared with autologous blood collected directly from the thoracic cavity after heart explantation 1:4 (blood:solution) (Table 1).
|Components (mM)||Custodiol-LP||del Nido-LP|
|Carrier||Sterile water||Plasma-Lyte A®|
|Potassium hydrogen 2-ketoglutarate||1||__|
|Sodium acetate trihydrate||__||20.34|
|Drugs concentration (del Nido-LP without added blood)|
Immunoblot by Western Blot Technique
The total protein extract with 50 µg per left ventricular sample was applied on 12% polyacrylamide gel (SDS-PAGE). Separation of the proteins of interest was performed by electrophoresis in mini-gel cell (Mini-PROTEAN II Cel® Bio-Rad) with buffer solution for electrophoresis previously diluted. Proteins were then transferred to a nitrocellulose membrane using electrotransfer equipment (Trans-Blot® Turbo(tm) Transfer System Bio-Rad). After transference, membranes were blocked with milk for subsequent incubation with primary alpha-fodrin (Abcam®, ab39165) at 4°C with constant stirring overnight (14-16 hours). These membranes were then washed with PBS solution and incubated in a chemiluminescent solution (Thermo Scientific Pierce ECL Western Blotting Substrate). Images were obtained by the multi-function system (Gel Logic Imaging System®, Rochester, NY, USA) to capture chemiluminescent reactions. All images were quantified by densitometry and normalized by colourimetric method with Ponceau.
All data were expressed as percentage of recovery and as mean and standard error of mean (SEM). The hemodynamic data were normalized with baseline values. Analyses were performed by 2-way ANOVA with Sidak's post-hoc test for multiple comparisons. Comparison of protein expression was performed using non-parametric Student t-test. Statistical significance was assumed P<0.05. All statistical analyses were performed using GraphPad® Prism 6 software.
Functional Left Ventricle Analysis
Two hearts from the control group were excluded due to ventricular fibrillation and no beating recovery after ischemia. Lower levels of developed pressure (Figure 1A) and RPP (Figure 1B) recovery were found in the control group than in Custodiol-LP and del Nido-LP groups, respectively. However, no relevant differences among the cardioplegic solution groups were found with these variables. Relevant lower levels of maximum dP/dt (Figure 1C) and minimum dP/dt (Figure 1D) were found in the control group than in Custodiol-LP and del Nido-LP groups, respectively. However, at 90 minutes of reperfusion, higher levels of maximum dP/dt (Figure 1C) and minimum dP/dt (Figure 1D) were found in del Nido-LP group than in Custodiol-LP.
CR levels found in the control group were higher than in Custodiol-LP group up to 60 minutes of reperfusion (Figure 2). Compared to del Nido-LP group, the control group showed high levels of CR throughout reperfusion. However, del Nido-LP group showed lower levels of CR than Custodiol-LP group at 90 minutes of reperfusion (Figure 2).
Myocardial global IR insult is well known to promote multifactorial effects on cellular metabolism resulting in irreversible damage to the heart function. Cardioplegic solutions with pharmacological combination as an alternative to provide further myocardial protection have encouraged researchers to carry out different combinations. Therefore, the present study evaluated pharmacological modifications with sodium inhibitor channels and potassium channel openers added to clinical relevant cardioplegic solutions, Custodiol and del Nido.
The potassium channel opener pinacidil has two main effects: vasodilatation and contractility reduction, due to its effect on potassium efflux avoiding calcium overload into the cardiomyocytes. In experimental models, pinacidil induced cardiac arrest by polarization, consequently reducing the adenosine triphosphate (ATP) consumption, compared to the cardiac arrest induced by depolarization[17,18]. Pinacidil has a non-selective pharmacological effect regarding the potassium channels' location, being able to activate them in the sarcolemma and mitochondria, since both have an important role in myocardial protection[17,19]. Differently, lidocaine is a reversible sodium channel blocker which has a pharmacological effect on calcium overload, preventing sodium-calcium exchanger reverse-mode action during IR[9,10]. In combination, these cardioplegic agents might improve cardiac resistance against long-term ischemia.
Custodiol-LP showed detrimental effects on cardiac function by the maximum and minimum dP/dt at 90 minutes of reperfusion compared to del Nido-LP. However, developed pressure and RPP parameters were similar throughout reperfusion time. CR analysis showed Custodiol-LP group with higher levels than del Nido-LP and marked reduction of coronary flow after 90 minutes of reperfusion.
The superiority of del Nido-LP solution may be associated with its greater ability to protect the myocardium over prolonged ischemia. The immunoblot assay performed by Western blot technique showed alpha-fodrin significant degradation in Custodiol-LP group compared to del Nido-LP. Alpha-fodrin present in extracellular matrix is consumed as a substrate for calpains after IR. The increase of calpain activity is correlated with myocardial injury and loss of contractile function[20-22]. Therefore, alpha-fodrin degradation is an indirect marker for cell integrity.
According to our findings, the addition of pharmacological agents to cardioplegic solutions showed greater myocardial protection in del Nido-LP group than in Custodiol-LP. Other components present in this solution may have possibly collaborated for these results. A single dose of the del Nido original formulation per se has shown great efficacy in pediatric and adult surgeries; perhaps, new solution proposals to induce long periods of ischemia should be based on its composition.
The addition of cardioplegic agents pinacidil and lidocaine provided greater protective capacity to del Nido-LP solution than to Custodiol-LP in hearts submitted to 3 hours of ischemia and 90 minutes of reperfusion. Contractile function data, according to variables of maximum dP/dt, minimum dP/dt and CR, showed a higher percentage of recovery in del Nido-LP group. Also, lower levels of alpha-fodrin degradation in del Nido-LP can support these findings showing higher myocardial protection against IR injury.
1. Ferguson ZG, Yarborough DE, Jarvis BL, Sistino JJ. Evidence-basedmedicine and myocardial protection: where is the evidence? Perfusion.2015;30(5):415-22.
2. Suleiman MS, Hancock M, Shukla R, Rajakaruna C, Angelini GD.Cardioplegic strategies to protect the hypertrophic heart during cardiacsurgery. Perfusion. 2011;26(Suppl 1):48-56. [MedLine]
3. Harvey B, Shann KG, Fitzgerald D, Mejak B, Likosky DS, Puis L, etal; American Society of ExtraCorporeal Technology's International Consortium forEvidence-Based Perfusion and Pediatric Perfusion Committee. Internationalpediatric perfusion practice: 2011 survey results. J Extra Corpor Technol.2012;44(4):186-93.
4. Groenewoud AF, Buchholz B, Gubernatis F, Hölscher M, Hoyer J, IsemerF, et al. First results of the multicenter study of HTK protection for kidneytransplants. Transplant Proc. 1990;22(5):2212.
5. Hölscher M, Groenewoud AF. Current status of the HTK solution ofBretschneider in organ preservation. Transplant Proc.1991;23(5):2334-7.
6. Edelman JJ, Seco M, Dunne B, Matzelle SJ, Murphy M, Joshi P, et al.Custodiol for myocardial protection and preservation: a systematic review. AnnCardiothorac Surg. 2013;2(6):717-28.
7. Lee S, Huang CS, Kawamura T, Shigemura N, Stolz DB, Billiar TR, etal. Superior myocardial preservation with HTK solution over Celsior in rathearts with prolonged cold ischemia. Surgery.2010;148(2):463-73.
8. Oliveira MA, Brandi AC, Santos CA, Botelho PH, Cortez JL, Braile DM.Modes of induced cardiac arrest: hyperkalemia and hypocalcemia-literaturereview. Rev Bras Cir Cardiovasc. 2014;29(3):432-6.
9. O'Blenes SB, Friesen CH, Ali A, Howlett S. Protecting the aged heartduring cardiac surgery: the potential benefits of del Nido cardioplegia. JThorac Cardiovasc Surg. 2011;141(3):762-70.
10. Govindapillai A, Hua R, Rose R, Friesen CH, O'Blenes SB. Protectingthe aged heart during cardiac surgery: use of del Nido cardioplegia providessuperior functional recovery in isolated hearts. J Thorac Cardiovasc Surg.2013;146(4):940-8.
11. Matte GS, del Nido PJ. History and use of del Nido cardioplegiasolution at Boston Children's Hospital. J Extra Corpor Technol.2012;44(3):98-103. [MedLine]
12. Betrián Blasco P, Antúnez Jiménez MI, Falcón González LH, SuárezCabrera P. Neonatal life-threatening arrhythmia responding to lidocaine, aprobable LQTS3. Int J Cardiol. 2007;117(2):e61-3.
13. van Emous JG, Nederhoff MG, Ruigrok TJ, van Echteld CJ. The role ofthe Na+ channel in the accumulation of intracellular Na+ during myocardialischemia: consequences for post-ischemic recovery. J Mol Cell Cardiol.1997;29(1):85-96. [MedLine]
14. Reichert K, Pereira do Carmo HR, Galluce Torina A, Diógenes deCarvalho D, Carvalho Sposito A, Souza Vilarinho KA, et al. Atorvastatin improvesventricular remodeling after myocardial infarction by interfering with collagenmetabolism. PLoS One. 2016;11(11):e0166845. [MedLine]
15. Yamamoto H, Yamamoto F. Myocardial protection in cardiac surgery: ahistorical review from the beginning to the current topics. Gen ThoracCardiovasc Surg. 2013;61(9):485-96.
16. Lawton JS, Harrington GC, Allen CT, Hsia PW, Damiano RJ Jr.Myocardial protection with pinacidil cardioplegia in the blood-perfused heart.Ann Thorac Surg. 1996;61(6):1680-8.
17. Yang L, Yu T. Prolonged donor heart preservation with pinacidil: therole of mitochondria and the mitochondrial adenosine triphosphate-sensitivepotassium channel. J Thorac Cardiovasc Surg.2010;139(4):1057-63.
18. Ikizler M, Dernek S, Sevin B, Maxey TS, Kural T. Improved myocardialfunction with the addition of pinacidil to custodiol. Transplantation.2002;74(12):1666-71.
19. Testai L, Rapposelli S, Calderone V. Cardiac ATP-sensitive potassiumchannels: a potential target for an anti-ischaemic pharmacological strategy.Cardiovasc Hematol Agents Med Chem. 2007;5(1):79-90. [MedLine]
20. Chen M, Won DJ, Krajewski S, Gottlieb RA. Calpain and mitochondriain ischemia/reperfusion injury. J Biol Chem.2002;277(32):29181-6.
21. Hanna RA, Campbell RL, Davies PL. Calcium-bound structure of calpainand its mechanism of inhibition by calpastatin. Nature.2008;456(7220):409-12.
22. Hernando V, Inserte J, Sartorio CL, Parra VM, Poncelas-Nozal M,Garcia-Dorado D. Calpain translocation and activation as pharmacological targetsduring myocardial ischemia/reperfusion. J Mol Cell Cardiol.2010;49(2):271-9.
Financial support: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2012/09130-1.
No conflict of interest.
Authors' roles & responsibilities
HPC Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published
KR Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published
DDC Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published
LMSF Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published
KV Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published
PO Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published
OP Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published
Article receive on Wednesday, December 20, 2017